Feature

Stopping anti-TNF drugs in PsA has high rebound risk

Publish date: October 26, 2017

 

FROM JOURNAL OF RHEUMATOLOGY

Pages

Recommended Reading

Children with psoriasis face multitude of comorbidities
MDedge Family Medicine
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Family Medicine
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Family Medicine
Ultrasound’s value for arthralgia may be to rule out IA
MDedge Family Medicine
Smoking linked to increased psoriasis risk
MDedge Family Medicine
Launch of adalimumab biosimilar Amjevita postponed
MDedge Family Medicine
Biologic approved for moderate to severe psoriasis in adolescents
MDedge Family Medicine
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Family Medicine
Biosimilars poised to save $54 billion over the next decade
MDedge Family Medicine
Swedish study finds low risk of developing psoriasis in bariatric surgery patients
MDedge Family Medicine

Related Articles